A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of OMS906 in PNH Patients With a Sub-optimal Response to the C5 Inhibitor, Ravulizumab
Latest Information Update: 13 Oct 2025
At a glance
- Drugs Zaltenibart (Primary) ; Zaltenibart (Primary) ; Ravulizumab
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Proof of concept
- Sponsors Omeros Corporation
Most Recent Events
- 01 Oct 2025 Status changed from active, no longer recruiting to completed.
- 08 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2023 Trial design presented at the 28th Congress of the European Haematology Association